Oslo, Norway, 27 October 2026 - Photocure ASA (OSE: PHO) has issued 200,000 share options to its new Chief Financial Officer, Mr. Dennis Camporeale at an exercise price of NOK 54.98 per share. The exercise price is equal to the weighted average share price 30 trading days before day of grant with an additional premium of 10% on top of the calculated average price.
The options are granted in accordance with Photocure's long term incentive program and the company's guidelines for remuneration of senior executives, as approved by Photocure's annual general meeting held 26 June 2026. The share option program and properties of the options are further described in the guidelines.
Primary insider notifications pursuant to the market abuse regulation article 19 are attached.
For more information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Priyam Shah
Vice President Investor Relations
Tel: +17176815072
Email: priyam.shah@photocure.com
About Photocure AS
Photocure is a commercial diagnostic company with global reach, committed to driving progress in uro-oncology precision diagnostics, delivering meaningful advances for patients with urological cancers. Our unique core technology has led to better health outcomes for patients worldwide. The company aims to provide an array of transformative solutions that help physicians with timely diagnostic information, to inform more personalized decisions on how best to manage each individual patient. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit www.photocure.com/news
This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading Act.